US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

28.94

-2.5300-8.04%

Volume:987.24K

Turnover:29.33M

Market Cap:1.06B

PE:-11.55

High:33.00

Open:31.86

Low:28.01

Close:31.47

52wk High:42.27

52wk Low:6.43

Shares:36.50M

Float Shares:14.96M

Volume Ratio:0.58

T/O Rate:6.60%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5062

EPS(LYR):-3.7760

ROE:-29.42%

ROA:-20.14%

PB:4.01

PE(LYR):-7.66

Loading ...

Overview Company News Filings

Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.

BUZZ-U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya Biosciences

Top Premarket Gainers

MT Newswires Live

Stock Track | Rapport Therapeutics Soars 171% Pre-Market on Positive Phase 2a Results for Seizure Drug

Stock Track | Rapport Therapeutics Soars 171% Pre-market on Positive Phase 2a Results for Seizure Drug

Rapport Reports Positive Focal Onset Seizures Trial Results

Rapport Therapeutics Reports Positive Phase 2a Trial Results

BUZZ-Rapport Therapeutics surges after seizure drug meets main goals in mid-stage trial

Rapport Therapeutics Shares up 75.5% Premarket on Mid-Stage Trial Data for Focal Onset Seizures Treatment

THOMSON REUTERS

Rapport Therapeutics Announces Successful Phase 2a Trial Results for RAP-219 in Treating Focal Onset Seizures, Plans Phase 3 Trials

Rapport Announces Positive Topline Results From Phase 2a Clinical Trial of Rap-219 in Patients With Focal Onset Seizures

THOMSON REUTERS

Rapport Therapeutics Inc - Plans End-of-Phase 2 Meeting With FDA in Q4 2025

THOMSON REUTERS

Rapport Therapeutics Inc - Patients Achieve 77.8% Seizure Reduction, 24% Seizure Freedom

THOMSON REUTERS

Rapport Therapeutics Inc - Trial Meets Primary Endpoints, Rap-219 Well Tolerated

THOMSON REUTERS

Rapport Therapeutics Inc - Rap-219 Well-Tolerated With Mild Adverse Events

THOMSON REUTERS

Rapport Therapeutics to Reveal Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on September 8, 2025

David Bredt, Chief Scientific Officer, Reports Disposal of Common Shares of Rapport Therapeutics Inc

Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

BRIEF-Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business Update

Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAPP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":28.94,"timestamp":1757437793255,"preClose":31.47,"halted":0,"volume":987240,"delay":0,"floatShares":14959986,"shares":36497920,"eps":-2.506155,"marketStatus":"Trading","change":-2.53,"latestTime":"09-09 13:09:59 EDT","open":31.86,"high":32.9991,"low":28.01,"amount":29333960.844,"amplitude":0.158535,"askPrice":29.04,"askSize":100,"bidPrice":28.78,"bidSize":13,"shortable":0,"etf":0,"ttmEps":-2.506155,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1757448000000},"marketStatusCode":2,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":31.47,"preHourTrading":{"tag":"盘前","latestPrice":31.95,"preClose":31.47,"latestTime":"09:29 EDT","volume":25706,"amount":801983.7311539999,"timestamp":1757424599067},"postHourTrading":{"tag":"盘后","latestPrice":31.5,"preClose":31.47,"latestTime":"19:59 EDT","volume":155398,"amount":4591762.383,"timestamp":1757375999999},"volumeRatio":0.576857,"impliedVol":0.9057,"impliedVolPercentile":0.5051},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14959986,"roa":"-20.14%","roe":"-29.42%","lyrEps":-3.775953,"volumeRatio":0.576857,"shares":36497920,"dividePrice":0,"high":32.9991,"amplitude":0.158535,"preClose":31.47,"low":28.01,"week52Low":6.43,"pbRate":"4.01","week52High":42.2685,"institutionHeld":0,"latestPrice":28.94,"committee":-0.769912,"eps":-2.506155,"divideRate":0,"volume":987240,"delay":0,"ttmEps":-2.506155,"open":31.86,"prevYearClose":17.74,"prevWeekClose":14.36,"prevMonthClose":17.63,"prevQuarterClose":11.37,"fiveDayClose":16.37,"twentyDayClose":14.28,"sixtyDayClose":11.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2025-05-08","symbol":"RAPP","fiscalQuarterEnding":"2025/03","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1754712000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-09-08","current":-5.934756,"percent":0.703822,"low":-19.654107,"twenty":-13.106883,"median":-8.211706,"eighty":-5.127911,"high":-3.640031,"avg":-9.263818,"sd":4.169455,"marketCap":524110131},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-08","current":-5.934756,"twenty":-13.106883,"median":-8.211706,"eighty":-5.127911,"marketCap":524110131}],"updateTime":1757437440330},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2565268615","title":"Rapport Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2565268615","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565268615?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:53","pubTimestamp":1757332380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 08, 2025 07:53 ET (11:53 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","LENZ"],"gpt_icon":0},{"id":"2565685054","title":"BUZZ-U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2565685054","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565685054?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:37","pubTimestamp":1757331443,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Veeva, Gold miners, Ideaya BiosciencesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL6N3UV0JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","LU0456854461.SGD","LU1430597077.USD","LU0390135506.SGD","BK4089","BK4526","NEM","BK4519","BK4534","RAPP","LU0368265764.SGD","LU0788108826.HKD","DNTH","IE00B19Z9P08.USD","NFE","BK4532","BK4147","IE00B19Z9Z06.USD","LU0055631609.USD","LU0498741114.HKD","LU1280957306.USD","IDYA","LU0612318971.USD","BK4588","LU1223082196.USD","LU0390135332.USD","LU0788109121.HKD","VEEV","BK4144","LU0278409577.USD","LU0654597011.USD","LU0390135688.USD","DQ","LU0266512127.USD","LU0724618789.USD","LU1861559042.SGD","BK4167","BK4139","LU2498475776.HKD","SATS","BK4613","LU1223082519.USD","BK4138","BK4585","LU0300738605.USD","LU0289739699.SGD","BK4570","BK4127"],"gpt_icon":1},{"id":"2565850806","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2565850806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565850806?lang=en_us&edition=fundamental","pubTime":"2025-09-08 19:36","pubTimestamp":1757331417,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics  shares were 165% higher pre-bell Monday after the company said that a phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint.Forward Industries  stock was up 102% after the company said it has secured $1.65 billion for its Solana treasury strategy.Seres Therapeutics  shares were 34% higher following a 3% increase in the previous session.EchoStar  stock was up 19% after the company said it signed a deal to sell its AWS-4 and H-block spectrum licenses to SpaceX for $17 billion.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FORD","BK4007","BK4202","BK4139","SATS","SOL.USD.HKCC","BK4100","RAPP","BK4145","MCRB","BK4089"],"gpt_icon":0},{"id":"1100322655","title":"Stock Track | Rapport Therapeutics Soars 171% Pre-Market on Positive Phase 2a Results for Seizure Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1100322655","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100322655?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:46","pubTimestamp":1757328398,"startTime":"0","endTime":"0","summary":"Shares of Rapport Therapeutics, Inc. (RAPP) are skyrocketing in pre-market trading, surging an impressive 171.59% following the announcement of positive topline results from its Phase 2a clinical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RAPP"],"gpt_icon":0},{"id":"1123963598","title":"Stock Track | Rapport Therapeutics Soars 171% Pre-market on Positive Phase 2a Results for Seizure Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1123963598","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123963598?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:46","pubTimestamp":1757328382,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. (RAPP) saw its stock skyrocket 171.59% in pre-market trading on Monday, following the announcement of positive topline results from its Phase 2a clinical trial of RAP-219,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["RAPP"],"gpt_icon":0},{"id":"2565688479","title":"Rapport Reports Positive Focal Onset Seizures Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2565688479","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565688479?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:39","pubTimestamp":1757327943,"startTime":"0","endTime":"0","summary":"Sept 8 (Reuters) - Rapport Therapeutics Inc ::*RAPPORT ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2A CLINICAL TRIAL OF RAP-219 IN PATIENTS WITH FOCAL ONSET SEIZURES*RAPPORT THERAPEUTICS INC - TRIAL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nRSD7Xhr2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2565881686","title":"Rapport Therapeutics Reports Positive Phase 2a Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2565881686","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565881686?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:29","pubTimestamp":1757327358,"startTime":"0","endTime":"0","summary":"An update from Rapport Therapeutics, Inc. ( ($RAPP) ) is now available. On September 8, 2025, Rapport Therapeutics announced positive topline resul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-positive-phase-2a-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-positive-phase-2a-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RAPP","BK4007","LENZ","BK4539"],"gpt_icon":0},{"id":"2565688825","title":"BUZZ-Rapport Therapeutics surges after seizure drug meets main goals in mid-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2565688825","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565688825?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:27","pubTimestamp":1757327262,"startTime":"0","endTime":"0","summary":"BUZZ-Rapport Therapeutics surges after seizure drug meets main goals in mid-stage trial** Shares of drug developer Rapport Therapeutics RAPP.O more than double to $30 premarket** RAPP's experimental o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL6N3UV0HI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2565654500","title":"Rapport Therapeutics Shares up 75.5% Premarket on Mid-Stage Trial Data for Focal Onset Seizures Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2565654500","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565654500?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:09","pubTimestamp":1757326187,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nL3N3UV0O9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2565500885","title":"Rapport Therapeutics Announces Successful Phase 2a Trial Results for RAP-219 in Treating Focal Onset Seizures, Plans Phase 3 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500885","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500885?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325620,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Announces Successful Phase 2a Trial Results for RAP-219 in Treating Focal Onset Seizures, Plans Phase 3 Trials. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL2sWxwb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4588","IE00B64PRP62.GBP","BK4585","NDAQ","LU2095319765.USD","RAPP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD","LU0314104364.USD","LU2210149790.SGD","BK4007","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2565507210","title":"Rapport Announces Positive Topline Results From Phase 2a Clinical Trial of Rap-219 in Patients With Focal Onset Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2565507210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565507210?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA7CHN4X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2565500894","title":"Rapport Therapeutics Inc - Plans End-of-Phase 2 Meeting With FDA in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500894?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA7CHN4X:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2565500810","title":"Rapport Therapeutics Inc - Patients Achieve 77.8% Seizure Reduction, 24% Seizure Freedom","url":"https://stock-news.laohu8.com/highlight/detail?id=2565500810","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565500810?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA7CHN4X:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2565350081","title":"Rapport Therapeutics Inc - Trial Meets Primary Endpoints, Rap-219 Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2565350081","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565350081?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA7CHN4X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2565070715","title":"Rapport Therapeutics Inc - Rap-219 Well-Tolerated With Mild Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2565070715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565070715?lang=en_us&edition=fundamental","pubTime":"2025-09-08 18:00","pubTimestamp":1757325600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nTUA7CHN4X:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2565598004","title":"Rapport Therapeutics to Reveal Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on September 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2565598004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565598004?lang=en_us&edition=fundamental","pubTime":"2025-09-06 04:05","pubTimestamp":1757102715,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc., a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological or psychiatric disorders, has announced that it will present topline results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures. The results will be disclosed during a conference call and live webcast scheduled for September 8, 2025, at 8:00 am ET. Interested parties can access the live broadcast via a webcast link or by dialing into the conference call with the provided phone numbers and conference ID. A replay of the webcast will be available for 90 days in the \"Investors\" section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDLbqzBXf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","NDAQ","BK4112","LU2095319765.USD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","RAPP","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4007","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2560135759","title":"David Bredt, Chief Scientific Officer, Reports Disposal of Common Shares of Rapport Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2560135759","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560135759?lang=en_us&edition=fundamental","pubTime":"2025-08-19 05:14","pubTimestamp":1755551699,"startTime":"0","endTime":"0","summary":"David Bredt, Chief Scientific Officer of Rapport Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL5dxGlJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2557559812","title":"Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557559812","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557559812?lang=en_us&edition=fundamental","pubTime":"2025-08-08 01:46","pubTimestamp":1754588777,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryRapport Therapeutics Inc RAPP.OQ reported a quarterly adjusted loss of 75 cents per share for the quarter ended","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nL8N3TZ2TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"gpt_icon":0},{"id":"2557565527","title":"BRIEF-Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2557565527","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557565527?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:32","pubTimestamp":1754569934,"startTime":"0","endTime":"0","summary":"BRIEF-Rapport Therapeutics Reports Second Quarter 2025 Financials And Provides Business UpdateAug 7 (Reuters) - Rapport Therapeutics Inc RAPP.O:RAPPORT THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUA8YGNZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2557065552","title":"Rapport Therapeutics Q2 EPS $(0.75) Beats $(0.85) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557065552","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557065552?lang=en_us&edition=fundamental","pubTime":"2025-08-07 19:16","pubTimestamp":1754565377,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.85) by 11.45 percent. This is a 55.88 percent increase over losses of $(1.70) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46957788/rapport-therapeutics-q2-eps-0-75-beats-0-85-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}